DEAL ANNOUNCEMENT
Corporate Finance Adviser, Isosceles Finance is delighted to announce that their client, Ridgeway Biologicals (a leading supplier of autogenous vaccines for production animals and aquaculture) has been acquired by (https://idt-biologika.com/) IDT Biologika. The transaction completed on 1st January, 2017. Isosceles acted as exclusive corporate finance adviser to the management team and shareholders of Ridgeway Biologicals.
Isosceles’ blend of corporate finance and accounting skills proved invaluable
“We are excited by the opportunity that IDT brings us to move our services internationally”, says Dr. Tim Wallis, Managing Director of Ridgeway. “Currently, antibiotics are used in farm animals in the absence of alternatives to control disease, such as effective vaccines for disease prevention. There is huge pressure to reduce antibiotic usage and autogenous vaccines, formulated to the specific requirements of our customers, should be able to help with this aim.”
Dr. Wallis, further added “Isosceles have provided a tremendous level of support throughout. They ran an effective process and identified an international buyer outside of our immediate network of business. Their blend of corporate finance and accounting skills proved invaluable.”
IDT Biologika perfect strategic and operational fit for Ridgeway
“Tim has created a very successful autogenous vaccine business which created significant interest from several potential buyers”, commented Mike O’Connell, CEO of Isosceles. “We are delighted to have secured IDT as the acquirer. They are the perfect strategic and operational fit for Ridgeway as they seek to strengthen their market dominance within the autogenous vaccine sector.”
Read the full press release here
Isosceles finance, business and corporate advisors to ambitious companies
